Tempus AI, Inc. (NASDAQ:TEM) CAO Sells $125,545.06 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci sold 1,858 shares of Tempus AI stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $67.57, for a total transaction of $125,545.06. Following the completion of the sale, the chief accounting officer now owns 55,379 shares of the company’s stock, valued at $3,741,959.03. This trade represents a 3.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tempus AI Stock Up 6.1 %

Tempus AI stock opened at $68.96 on Friday. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock’s 50 day moving average is $44.36 and its 200 day moving average is $48.84.

Institutional Trading of Tempus AI

Several large investors have recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in Tempus AI during the 3rd quarter valued at about $30,000. Geode Capital Management LLC raised its position in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the period. FNY Investment Advisers LLC purchased a new position in Tempus AI in the fourth quarter valued at approximately $67,000. IFP Advisors Inc bought a new position in shares of Tempus AI during the 4th quarter worth $76,000. Finally, US Bancorp DE bought a new stake in shares of Tempus AI in the fourth quarter valued at approximately $80,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEM has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. TD Cowen reissued a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.